The FDA wants to pull its approval of a drug. It’s not so easy.
The regulator says Tavneos was approved on the basis of manipulated study data. Should patients still have access to it?
The regulator says Tavneos was approved on the basis of manipulated study data. Should patients still have access to it? This story matters for AI & Agent Economy readers tracking app. Reported by arstechnica.com. Read the full original at the source link below.
Originally reported by arstechnica.com. AppNewsletter.com curates and briefs the ai & agent economy stories that matter. Our editorial policy →
Get the daily app signal